Jasper Therapeutics- Warrants (24/09/2026) Overview
Is JSPRW undervalued? Intrinsic value estimate stands at $1.4.
Get informed when a big investor buys or sells
+ Follow$1.43
Undervalued by 716100.0% based on the discounted cash flow analysis.
Jasper Therapeutics- Warrants (24/09/2026) posts a DCF fair value of $1.4. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
Markets price JSPRW on many factors — sentiment, liquidity, and near-term news — while DCF focuses on long-run cash flows. The current fair-value estimate of $1.4 sits 716100.0% above the live price. Large gaps can highlight opportunity or model risk; the charts on this page help you see how the estimate has moved over time.
Context for JSPRW's DCF fair value usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Jasper Therapeutics- Warrants (24/09/2026)'s other metric pages and overview cover the third.
